免疫检查点抑制剂联合重组人内皮抑素及化疗作为晚期非小细胞肺癌一线治疗的疗效与安全性
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
作者信息
Fu Silv, Huang Hongxiang, Shang Kai, Tu Ganjie, Zhong Peiyuan, Li Siling, Zhu Xie, Peng Sujuan, Liu Yangyang, Lu Zhihui, Chen Li
机构信息
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Department of Radiotherapy, Jiangxi Cancer Hospital, Nanchang, 330029, China.
出版信息
Future Oncol. 2023 Jan;19(2):147-158. doi: 10.2217/fon-2022-0861. Epub 2023 Feb 13.
To assess the efficacy and safety of combination of PD-1 inhibitors, recombinant human endostatin (Rh-endostatin) and chemotherapy as first-line treatment for advanced non-small-cell lung cancer (NSCLC). A total of 100 patients with advanced NSCLC were retrospectively reviewed and analyzed (58 in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy; 42 in the group receiving Rh-endostatin and chemotherapy). The primary end point was progression-free survival. Patients in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy had significantly improved progression-free survival (10.2 vs 6.5 months; p < 0.001) and objective response rate (67.2 vs 42.9%; p = 0.015), with acceptable toxicity. Our study showed the superiority of combination therapy of PD-1 inhibitors and Rh-endostatin as first-line treatment for advanced NSCLC.
评估程序性死亡受体1（PD-1）抑制剂、重组人血管内皮抑素（Rh-血管内皮抑素）与化疗联合作为晚期非小细胞肺癌（NSCLC）一线治疗方案的疗效和安全性。回顾性分析了100例晚期NSCLC患者（58例接受PD-1抑制剂联合Rh-血管内皮抑素及化疗；42例接受Rh-血管内皮抑素及化疗）。主要终点为无进展生存期。接受PD-1抑制剂联合Rh-血管内皮抑素及化疗的患者无进展生存期显著改善（10.2个月对6.5个月；p<0.001），客观缓解率也显著提高（67.2%对42.9%；p=0.015），且毒性可接受。我们的研究显示，PD-1抑制剂与Rh-血管内皮抑素联合治疗作为晚期NSCLC的一线治疗方案具有优越性。
Zotero 插件